Navigation Links
Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea

ent compliance. Since it is commonly known that an inverse relationship exists between compliance and dosing frequency, this finding holds significant promise for successful treatment of the papulopustular form of rosacea targeted for treatment by anti- inflammatory dose doxycycline.

The study concludes that "anti-inflammatory dose doxycycline is the only tetracycline agent proven to be effective for the treatment of rosacea in pivotal phase III clinical trials and exhibits a pharmacokinetic profile that separates the anti-inflammatory effects from antibiotic activities."

"The advent of this systemic treatment for rosacea portends a greater population of patients who experience satisfaction from the regimen recommended by their physician because the therapy is easy to comply with and avoids the consequences of antibiotic exposure for a disease where it has not been shown that an antibiotic effect is needed," said Dr. Del Rosso.

About CollaGenex

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company currently focused on developing and marketing proprietary, innovative medical therapies to the dermatology market. In July 2006, CollaGenex launched Oracea(R), the first FDA-approved systemic product for the treatment of rosacea. CollaGenex's professional dermatology sales force also markets Pandel(R), a prescription topical corticosteroid licensed from Altana, Inc., Alcortin(R) (1% iodoquinol and 2% hydrocortisone), a prescription topical antifungal steroid combination, and Novacort(R) (2% hydrocortisone acetate and 1% pramoxine HCl), a prescription topical steroid and anesthetic. Alcortin and Novacort are marketed by the Company under a Promotion and Cooperation agreement with Primus Pharmaceuticals, Inc. CollaGenex is conducting a 400-patient, Phase II dose-finding study to evaluate its second dermatology candidate, incyclinide, for the treatment of acne. CollaGenex is also conducting Phase I clinical trials to evaluate COL-1
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting
6. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
7. King Pharmaceuticals Announces Plan to Report Positive Data from Phase III Clinical Trial Evaluating the Combination of Altace with Hydrochlorothiazide
8. Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for Psychotic Major Depression Misses Primary Endpoint
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
(Date:7/31/2014)... 31, 2014 Marken announced today the expansion ... meet the clinical trial logistics growth in Central and ... facility will continue to serve as a regional center ... from the region, and will provide additional storage capacity. ... combine its office and warehouse into a single facility, ...
(Date:7/30/2014)... July 30, 2014  There is still time ... success. The 10th Annual Institute for Supply Management ... Excellence in Supply Management is open for submissions.  ... understanding and importance of supply management by recognizing ... best supply management practices.  Entries are due August ...
(Date:7/30/2014)... 2014 In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to the ... internet on Thursday, August 7, 2014 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
Breaking Medicine Technology:Marken Expands Miami Regional Logistics Center 2Institute for Supply Management, Michigan State University to recognize companies with excellent supply management practices 2DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2
... May 4, 2012 Medical device and medical ... their products meet quality standards and regulations at ... and product development to manufacturing and post-marketing activity. ... an increasingly competitive marketplace, medical device organizations are ...
... PARSIPPANY, N.J., May 4, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... DeFrancesco has been promoted to the position of Vice ... Ms. DeFrancesco reports to Charles Mayr, Chief Communications Officer ... Watson on June 1, 2012. In this ...
Cached Medicine Technology:Staffing and Performance Benchmarks for Quality Function Highlight New Medical Device Study 2Watson Names Lisa DeFrancesco Vice President, Global Investor Relations 2
(Date:7/31/2014)... Beverly Hills, CA (PRWEB) July 31, 2014 ... president George W. Bush recently underwent partial knee replacement surgery ... right knee less than two months earlier. The story also ... between the procedures and hopes to be back on the ... replacement surgery highlights the benefits of partial knee replacement. ...
(Date:7/31/2014)... 31, 2014 ProtonPACS, a division of ... the National Rural Health Association (NRHA), company officials announced ... understanding the needs of rural health providers nationwide. , ... Health Association,” said Dr. Mark Awh, President of Radsource. ... of ProtonPACS, we are also looking forward to learning ...
(Date:7/31/2014)... 2014) While it is known that members of the ... a new study finds that female enlistees and female ... civilian counterparts. This study was published today in ... on behalf of the Inter-University Seminar on Armed Forces ... Tedrow studied surveys of nearly 9,000 men and women ...
(Date:7/31/2014)... Staying happy in a relationship and loving for years ... get sucked into the logistical ruts they know as their ... kids. , That’s why Couples in Trouble Relationship Expert, ... to Reignite the Spark in Your Marriage TODAY” Guide as ... much better path to happiness, and a far less costly ...
(Date:7/31/2014)... 2014 According to new research ... Mycoprotein), by Type (Tofu, Tofu-Based Product, Tempeh, TVP, ... Global Trends & Forecasts to 2019", defines and ... analysis and forecasting of the market value of ... report also identifies the driving and restraining factors ...
Breaking Medicine News(10 mins):Health News:George W. Bush’s Surgery Highlights the Benefits of Partial Knee Replacement 2Health News:ProtonPACS Announces Pipeline Partnership with the National Rural Health Association. 2Health News:Women in military less likely to drink than civilian women 2Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 2Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3
... RESULTS, EUR,000,000 2008 ... 92.5 99.3 EBITDA* ... 14.0% 16.1% Current operating income* ... (2.8) (2.7) Net income ...
... central nervous system , , WEDNESDAY, July 30 (HealthDay News) ... depression, at least in mice. , According to the ... Istvan Mody, both of the David Geffen School of ... of a particular class of proteins called GABA receptors ...
... Data from 260 hospitals across the United States has ... to more accurately determine the severity of heart failure in ... mortality and more quickly identifying triage methods and treatment decisions. ... the Journal of the American College of Cardiology . ...
... for Universal, Health Coverage Proposal but Obstacles Remain, According ... ... 30 ,HealthLeaders-InterStudy, a leading provider of managed care market,intelligence, reports ... windfall for the state of New Mexico has resulted in ...
... recently,submitted its bid to the U.S. Department of ... third generation TRICARE South Region contract. If,awarded the ... active,duty, retired and participating reserve and National Guard ... on April 1, 2010., "It is TriServ,s ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) today ... and webcast to discuss the Company,s 2007 financial ... data.,The call will now be held on Friday, ... will issue its 2007 financial results and second-quarter ...
Cached Medicine News:Health News:PCAS : Half Result 2008 2Health News:Possible Cause of Postpartum Depression Pinpointed 2Health News:Possible Cause of Postpartum Depression Pinpointed 3Health News:New method assesses risks for heart failure patients 2Health News:Gov. Richardson's Healthcare Reform Agenda Gains New Life 2Health News:Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data 2
Solid 14 mm blades. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Open 14 mm blades of heavy 1 mm wire. Dull finish. Most popular size or model....
Open wire style blades allow complete manipulation of the phaco tip inside the eye. Lid control is excellent, exposure is maximized, and the likelihood of positive pressure is reduced....
Medicine Products: